KRAS-Targeted Therapy | Oncology Modality Intelligence

Description

List of Tables

KRAS spent four decades as oncology's most famous undruggable target, and its arrival as a druggable one has played out unevenly in Japan. Amgen's Lumakras is the only KRAS inhibitor approved and reimbursed in the country, which makes Japan simultaneously a validated market for the class and a strikingly under-contested one: adagrasib, approved in the US and Europe under Bristol Myers Squibb's ownership since the Mirati acquisition, has no Japanese entry. For a country carrying heavy colorectal and pancreatic cancer burdens - tumor types where KRAS mutation is the rule rather than the exception - the distance between biological relevance and therapeutic availability is unusually wide.

The tension is about which generation of the class Japan gets, and when. First-generation G12C inhibitors validated the target but left resistance, combination, and allele-coverage questions open. The next wave - Revolution Medicines' RAS(ON) multi-selective inhibitors led by daraxonrasib, Lilly's olomorasib, Roche's divarasib, and Chinese G12C agents from Jacobio and GenFleet - is designed around those weaknesses, and the pivotal programs now running will decide whether KRAS targeting expands from a NSCLC niche into the pancreatic and colorectal mainfields that matter most in Japan. Companion-diagnostic attach, combination partner strategy, and the sponsor-recruitment dynamics of Japan's unapproved-drug lists all sit unresolved around that core question.

This report maps the KRAS class from a Japanese vantage point. It explains the allele biology and testing infrastructure that define treatable populations, profiles Lumakras's Japanese position and the CodeBreaK program behind it, and walks asset by asset through the competing pipelines: adagrasib's absent entry, daraxonrasib and zoldonrasib, olomorasib, divarasib, Frontier Medicines, Erasca's pan-RAS approach, Verastem's pathway combinations, and the Chinese G12C developers. Chapters cover combination architectures, resistance mechanisms, biomarker-testing economics, and the BD opening created by Japan's thin coverage of the class.

The report serves biotech BD teams weighing Japan rights and licensing, companion-diagnostics firms, investors pricing KRAS exposure, and Japanese companies seeking in-licensing opportunities. It provides allele-level and program-level detail suited to deal screening and market-entry judgment.

Scope and Coverage: The report covers approved and pipeline KRAS-targeted agents relevant to Japan across NSCLC, colorectal, and pancreatic cancers, including G12C inhibitors, RAS(ON) multi-selective agents, pan-RAS programs, and pathway combinations. It profiles Amgen, Bristol Myers Squibb, Revolution Medicines, Lilly, Roche, Frontier Medicines, Erasca, Verastem, Jacobio, and GenFleet, and addresses biomarker-testing and regulatory pathways.

Report Highlights:

Explains Lumakras's Japanese position and the CodeBreaK trial program
Analyzes adagrasib's absence from Japan and the resulting market structure
Profiles RAS(ON) programs: daraxonrasib, zoldonrasib, and the RASolute trials
Covers olomorasib, divarasib, and Chinese G12C agents from Jacobio and GenFleet
Maps allele-specific treatable populations across NSCLC, CRC, and pancreatic cancer
Frames Japan entry, licensing, and companion-diagnostic opportunities in the class

Product Code: JPH-031

Table of Content

1. Executive Summary

2. KRAS-Targeted Therapy: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Amgen (US) - Lumakras (sotorasib); only approved KRAS G12C inhibitor in Japan
Bristol Myers Squibb (US) - adagrasib (Krazati) via the Mirati acquisition; no Japan entry to date
Revolution Medicines (US) - RAS(ON) inhibitors including daraxonrasib and zoldonrasib
Eli Lilly (US) - olomorasib KRAS G12C program
Roche (CH) - divarasib KRAS G12C program
Frontier Medicines (US) - KRAS G12C inhibitor program
Erasca (US) - pan-RAS and RAS-pathway pipeline
Boehringer Ingelheim (DE) - KRAS inhibitor research programs
Verastem (US) - RAS/MAPK pathway combinations
Jacobio (CN) - glecirasib KRAS G12C inhibitor
GenFleet (CN) - fulzerasib KRAS G12C inhibitor licensed to Innovent

Product Code: JPH-031

List of Tables

Table 1. KRAS Biology: Allele Distribution and Switch-Region Druggability
Table 2. KRAS Mutation Landscape Across Japanese NSCLC, CRC, and Pancreatic Populations
Table 3. KRAS Testing Infrastructure in Japan: NGS Panels and PCR Assays
Table 4. Companion-Diagnostic Attach Models for KRAS-Targeted Therapy
Table 5. Lumakras (Sotorasib): Mechanism and Japanese Label
Table 6. CodeBreaK Trial Program: Designs Across Lines and Combinations
Table 7. Lumakras Combination Development: Immunotherapy and SHP2 Pairings
Table 8. Adagrasib (Krazati): KRYSTAL Program and US-EU Status
Table 9. Adagrasib's Japan Absence: Regulatory and Commercial Explanation Framework
Table 10. Bristol Myers Squibb Mirati Acquisition: KRAS Asset Integration
Table 11. Revolution Medicines RAS(ON) Platform: Mechanistic Differentiation
Table 12. Daraxonrasib (RMC-6236): Program Design in Pancreatic Cancer
Table 13. RASolute 302 and Pancreatic Pivotal Strategy
Table 14. Zoldonrasib (RMC-9805) and Allele-Selective RAS(ON) Programs
Table 15. Elironrasib and RAS(ON) G12C-Selective Development
Table 16. Lilly Olomorasib: Program Design and Combination Strategy
Table 17. Roche Divarasib: Program Design and Inavolisib Combination Context
Table 18. Frontier Medicines KRAS G12C Program
Table 19. Erasca Pan-RAS and RAS-Pathway Pipeline
Table 20. Verastem RAS/MAPK Combination Programs: Avutometinib Context
Table 21. Boehringer Ingelheim KRAS Research Programs
Table 22. Jacobio Glecirasib: China Development and Out-Licensing Position
Table 23. GenFleet Fulzerasib and the Innovent Licensing Relationship
Table 24. China KRAS Developer Landscape and Licensing-Out Record
Table 25. Resistance Mechanisms to G12C Inhibition: RTK, MAPK, and Allele Switching
Table 26. Combination Architecture Framework for KRAS-Targeted Regimens
Table 27. G12D and Pan-KRAS Programs Relevant to Japan's CRC and Pancreatic Burden
Table 28. SOS1, SHP2, and Downstream Pathway Targeting Programs
Table 29. KRAS-Targeted Therapy in Japanese Treatment Guidelines
Table 30. PMDA Pathways and Unapproved-Drug List Status for KRAS Agents
Table 31. Sponsor-Recruitment Dynamics for KRAS Assets Lacking Japan Sponsors
Table 32. Trial-Enrollment Competition Among KRAS Programs in Asia
Table 33. Biomarker-Defined Population Funnels by Allele and Tumor Type
Table 34. Testing Turnaround and Referral Implications for KRAS-Directed Care
Table 35. Pricing and Reimbursement Precedents for Targeted Agents in Japan
Table 36. Competitive Positioning Matrix: KRAS Assets by Allele, Modality, and Stage
Table 37. Deal Benchmarks for KRAS-Asset Licensing
Table 38. Japan Entry Models for KRAS Developers: Solo, Partner, and Skip
Table 39. Scenario Framework: KRAS Class Coverage of Japan's Tumor Burden
Table 40. Risk Register: Resistance, Combination Toxicity, and Competitive Timing
Table 41. Indicator Dashboard for KRAS Class Monitoring
Table 42. Due-Diligence Checklist for KRAS-Asset Licensing
Table 43. Japanese In-Licensing Candidates: Domestic Company Appetite Map
Table 44. Stakeholder Position Map: Sponsors, Diagnostics, and Payers
Table 45. Real-World KRAS Testing Rates and Data Sources in Japan
Table 46. Pancreatic Cancer KRAS Program Detail: Line-of-Therapy Strategies
Table 47. Colorectal Cancer KRAS Program Detail: Combination Requirements
Table 48. NSCLC KRAS Program Detail: Post-Immunotherapy Positioning
Table 49. Horizon Scan: Molecular Glue and Next-Generation RAS Targeting
Table 50. Analytical Appendix: Trial Registries and Licensing Databases

List of Figures

Figure 1. KRAS Switch-Region Biology and Inhibitor Binding Model
Figure 2. Allele Distribution Map Across Japanese Tumor Types
Figure 3. KRAS Testing Infrastructure Diagram
Figure 4. Companion-Diagnostic Attach Model Flow
Figure 5. Lumakras Japanese Position Timeline
Figure 6. CodeBreaK Program Family Tree
Figure 7. Lumakras Combination Strategy Diagram
Figure 8. Adagrasib KRYSTAL Program Map
Figure 9. Adagrasib Japan Absence: Explanation Framework
Figure 10. Revolution Medicines RAS(ON) Mechanism Diagram
Figure 11. Daraxonrasib Pancreatic Program Map
Figure 12. RASolute 302 Pivotal Design Schematic
Figure 13. Allele-Selective RAS(ON) Program Tree
Figure 14. Olomorasib and Divarasib Program Schematics
Figure 15. Frontier, Erasca, and Verastem Program Map
Figure 16. China KRAS Developer Landscape
Figure 17. Jacobio and GenFleet Licensing Structure Diagrams
Figure 18. Resistance Mechanism Map to G12C Inhibition
Figure 19. Combination Architecture Framework
Figure 20. G12D and Pan-KRAS Program Map
Figure 21. Downstream Pathway Targeting Diagram
Figure 22. Guideline Positioning of KRAS Therapy in Japan
Figure 23. PMDA and Unapproved-Drug List Pathway
Figure 24. Sponsor-Recruitment Dynamics Diagram
Figure 25. Enrollment Competition Map in Asia
Figure 26. Allele-Defined Population Funnel
Figure 27. Testing Turnaround and Referral Flow
Figure 28. Pricing Precedent Map for Targeted Agents
Figure 29. Competitive Positioning Map: KRAS Assets
Figure 30. KRAS Licensing Deal Benchmark Framework
Figure 31. Japan Entry Model Decision Tree
Figure 32. Scenario Tree: KRAS Coverage of Japan's Tumor Burden
Figure 33. Risk Map: Resistance, Toxicity, and Timing
Figure 34. KRAS Class Monitoring Dashboard
Figure 35. Licensing Due-Diligence Flow
Figure 36. Domestic In-Licensing Appetite Map
Figure 37. Stakeholder Position Map
Figure 38. Real-World KRAS Testing Data Framework
Figure 39. Pancreatic Line-of-Therapy Strategy Diagram
Figure 40. Colorectal Combination Requirement Map
Figure 41. NSCLC Post-Immunotherapy Positioning Diagram
Figure 42. Molecular Glue Horizon Scan
Figure 43. Patient Journey from Biopsy to KRAS-Directed Therapy
Figure 44. Biomarker-Lab Readiness Framework
Figure 45. Sponsor Trial-Network Footprints in Japan
Figure 46. Investor KPI Dashboard for the KRAS Theme
Figure 47. Competitive Response Options for Incumbent Sponsors
Figure 48. Deal History Timeline in the KRAS Class
Figure 49. Synthesis: What Determines KRAS Class Value in Japan
Figure 50. Report Roadmap: Chapter Linkages to Reader Decisions

KRAS-Targeted Therapy | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. KRAS-Targeted Therapy: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures